---
schema_version: "secwatch.filing_event.v1"
accession: "0001739410-25-000029"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:27:15.770670+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rallybio Q4 net loss $11M, cash $65.5M; key trial data readouts in 2025

## Summary
- Q4 2024 net loss $11.0M ($0.25/share) vs $20.2M ($0.50/share) in Q4 2023; full-year loss $57.8M.
- Revenue $38k in Q4 2024 from J&J collaboration; zero revenue in year ago period.
- Cash, equivalents, and marketable securities $65.5M as of Dec 31, 2024; runway into 2H 2026.
- RLYB212 Phase 2 sentinel participant dosed; PK/safety data from 2nd trimester expected Q2 2025, at delivery Q3 2025.
- RLYB116 confirmatory PK/PD study to start Q2 2025; Cohorts 1 and 2 data in Q3/Q4 2025.

## SEC filing metadata
- accession: 0001739410-25-000029
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000173941025000029/0001739410-25-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000173941025000029/rlyb-20250313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739410-25-000029
- JSON: https://secwatch.observer/filing/0001739410-25-000029.json
- Plain text: https://secwatch.observer/filing/0001739410-25-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.